Thymidylate synthase polymorphisms in genomic DNA as clinical outcome predictors in a European population of advanced non-small cell lung cancer patients receiving pemetrexed
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1479-5876
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Thymidylate synthase polymorphisms in genomic DNA as clinical outcome predictors in a European population of advanced non-small cell lung cancer patients receiving pemetrexed ; volume:12 ; number:1 ; day:14 ; month:4 ; year:2014 ; pages:1-9 ; date:12.2014
Journal of translational medicine ; 12, Heft 1 (14.4.2014), 1-9, 12.2014
- Urheber
-
Arévalo, Estefanía
- Beteiligte Personen und Organisationen
-
Castañon, Eduardo
López, Inés
Salgado, Josefa
Collado, Víctor
Santisteban, Marta
Rodriguez-Ruiz, Maria
Martin, Patricia
Zubiri, Leire
Patiño-García, Ana
Rolfo, Christian
Gil-Bazo, Ignacio
SpringerLink (Online service)
- DOI
-
10.1186/1479-5876-12-98
- URN
-
urn:nbn:de:1111-2016041449858
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:01 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Arévalo, Estefanía
- Castañon, Eduardo
- López, Inés
- Salgado, Josefa
- Collado, Víctor
- Santisteban, Marta
- Rodriguez-Ruiz, Maria
- Martin, Patricia
- Zubiri, Leire
- Patiño-García, Ana
- Rolfo, Christian
- Gil-Bazo, Ignacio
- SpringerLink (Online service)
Ähnliche Objekte (12)
Thymidylate synthase expression as a predictive biomarker of pemetrexed sensitivity in advanced non-small cell lung cancer
Association of thymidylate synthase gene 3'-untranslated region polymorphism with sensitivity of non-small cell lung cancer to pemetrexed treatment: TS gene polymorphism and pemetrexed sensitivity in NSCLC
The pemetrexed-containing treatments in the non-small cell lung cancer, is -/low thymidylate synthase expression better than +/high thymidylate synthase expression: a meta-analysis
Pemetrexed for advanced non-small cell lung cancer patients with interstitial lung disease
Maintenance pemetrexed in nonsmall cell lung carcinoma: Outcome analysis from a tertiary care center
Under the Magnifying Glass: Searching for The Evidence of Pemetrexed in Nonsquamous Nonsmall Cell Lung Cancer
Pemetrexed plus cisplatin/carboplatin in previously treated locally advanced or metastatic non-small cell lung cancer patients
Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study
Phase i study of 'dose-dense' pemetrexed plus carboplatin/radiotherapy for locally advanced non-small cell lung carcinoma
Pemetrexed single agent chemotherapy in previously treated patients with locally advanced or metastatic non-small cell lung cancer
Correlation of toxicities and efficacies of pemetrexed with clinical factors and single-nucleotide polymorphisms: a prospective observational study
Thymidylate synthase gene (TYMS) polymorphisms in sporadic and hereditary breast cancer
Thymidylate synthase expression as a predictive biomarker of pemetrexed sensitivity in advanced non-small cell lung cancer
Association of thymidylate synthase gene 3'-untranslated region polymorphism with sensitivity of non-small cell lung cancer to pemetrexed treatment: TS gene polymorphism and pemetrexed sensitivity in NSCLC
The pemetrexed-containing treatments in the non-small cell lung cancer, is -/low thymidylate synthase expression better than +/high thymidylate synthase expression: a meta-analysis
Pemetrexed for advanced non-small cell lung cancer patients with interstitial lung disease
Maintenance pemetrexed in nonsmall cell lung carcinoma: Outcome analysis from a tertiary care center
Under the Magnifying Glass: Searching for The Evidence of Pemetrexed in Nonsquamous Nonsmall Cell Lung Cancer
Pemetrexed plus cisplatin/carboplatin in previously treated locally advanced or metastatic non-small cell lung cancer patients
Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study
Phase i study of 'dose-dense' pemetrexed plus carboplatin/radiotherapy for locally advanced non-small cell lung carcinoma
Pemetrexed single agent chemotherapy in previously treated patients with locally advanced or metastatic non-small cell lung cancer
Correlation of toxicities and efficacies of pemetrexed with clinical factors and single-nucleotide polymorphisms: a prospective observational study
Thymidylate synthase gene (TYMS) polymorphisms in sporadic and hereditary breast cancer
Thymidylate synthase expression as a predictive biomarker of pemetrexed sensitivity in advanced non-small cell lung cancer
Association of thymidylate synthase gene 3'-untranslated region polymorphism with sensitivity of non-small cell lung cancer to pemetrexed treatment: TS gene polymorphism and pemetrexed sensitivity in NSCLC
The pemetrexed-containing treatments in the non-small cell lung cancer, is -/low thymidylate synthase expression better than +/high thymidylate synthase expression: a meta-analysis
Pemetrexed for advanced non-small cell lung cancer patients with interstitial lung disease
Maintenance pemetrexed in nonsmall cell lung carcinoma: Outcome analysis from a tertiary care center
Under the Magnifying Glass: Searching for The Evidence of Pemetrexed in Nonsquamous Nonsmall Cell Lung Cancer
Pemetrexed plus cisplatin/carboplatin in previously treated locally advanced or metastatic non-small cell lung cancer patients
Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study
Phase i study of 'dose-dense' pemetrexed plus carboplatin/radiotherapy for locally advanced non-small cell lung carcinoma
Pemetrexed single agent chemotherapy in previously treated patients with locally advanced or metastatic non-small cell lung cancer
Correlation of toxicities and efficacies of pemetrexed with clinical factors and single-nucleotide polymorphisms: a prospective observational study